Skip to main content

Table 4 Major AEs of Targeted Therapies for CNS Lymphoma

From: Current and emerging therapies for primary central nervous system lymphoma

Targeted therapy

Adverse events

Events

Any grade

Grade≥3

ibrutinib [14, 70,71,72]

neutropenia

25%(5/20)~40%(6/15),

3.8%(2/52)~ 83%(15/18)

anemia

70%(14/20)~100%(15/15)

5%(1/20)~20%(3/15)

thrombocytopenia

70%(14/20)

10%(2/20)~72%(13/18)

febrile neutropenia

5%(1/25)

1.9%(1/52)~61%(11/18)

increased creatinine

27%(4/15)~30%(6/20)

27%(4/15)

increased ALT

3.8%(2/52)~80%(12/15)

7%(1/15)~10%(2/20)

diarrhea

3.8%(2/52)~25%(5/20)

7%(1/15)~11%(2/18)

prolonged APTT

20%(3/15)~30%(6/20)

10%(2/20)

infection

9.6%(5/52)~27%(4/15)

5.8%(3/52)~78%(14/18)

atrial fibrillation

3.8%(2/52)

1.9%(1/52)

lenalidomide [42, 76]

neutropenia

 

21.4%(3/14)~40%(20/50)

thrombocytopenia

 

10%(5/50)

anemia

 

4%(2/50)

infection

 

8%(4/50)~21.4%(3/14)

Pomalidomide [15]

neutropenia

100%(25/25)

20%(5/25)

thrombocytopenia

44%(11/25)

8%(2/25)

anemia

80%(20/25)

8%(2/25)

thromboembolism

8%(2/25)

 

infection

44%(11/25)

16%(4/25)

fatigue

40%(10/25)

8%(2/25)

dyspnea, hypoxia and/or respiratory failure

16%(4/25)

16%(4/25)

nivolumab [77]

pruritus

20%(1/5)

 

fatigue

20%(1/5)

 

renal insufficiency

20%(1/5)

20%(1/5)

NGR-hTNF [78]

neutropenia

89%(25/28)

85%(24/28)

thrombocytopenia

85%(24/28)

61%(17/28)

anemia

85%(24/28)

21%(6/28)

febrile neutropenia

14%(4/28)

14%(4/28)

infection

14%(4/28)

14%(4/28)

deep vein thrombosis

7%(2/28)

7%(2/28)

infusion reaction

32%(9/28)

 

hepatotoxicity

50%(14/28)

18%(5/28)

  1. Abbreviations: ALT alanine aminotransferase, APTT activated partial thromboplastin time